Lukasz Wieteska
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Lukasz Wieteska has a total of 66 co-authors. Here are the top co-authors by number of shared publications:
- Anne Paulien Drenth
Division of Molecular Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands
15 shared publications - Bjørn Siteur
Mouse Clinic for Cancer and Aging, Netherlands Cancer Institute, Amsterdam, The Netherlands
15 shared publications - Catrin Lutz
Division of Molecular Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands
15 shared publications - Chi-Chuan Lin
School of Molecular and Cellular Biology, Centre for Plant Sciences and Astbury Centre for Structural Molecular Biology University of Leeds Leeds LS2 9JT UK
15 shared publications - Daniel Zingg
Division of Molecular Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands
15 shared publications - Eline van der Burg
Division of Molecular Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands
15 shared publications
Latest Publications
- Open Access
Pro-domain-dependent folding and co-receptor-mediated targeting to optimize an antagonistic TGF-β monomer for gene-based delivery
Transforming growth factor-beta (TGF-β), a potent promoter of extracellular matrix deposition and suppressor of infiltrating immunity, has arisen as an attractive target for improving outcomes in tissue fibrosis and cancer immune therapy. Despite the promise of TGF-β inhibitors for attenuating the progression of fibrotic disorders or as adjuncts for cancer immunotherapy, current systemically administered inhibitors that target the ligand or receptors have significant on-target liabilities, including cardiotoxicity and development of pre-malignant cutaneous squamous lesions. Recently, an engineered mini monomer of TGF-β (mmTGF-β), which potently and specifically inhibits TGF-β activity, was shown to strongly synergize with checkpoint inhibitors to suppress cancer progression in an aggressive model of melanoma when genetically delivered using an engineered form of vaccinia virus that preferentially infects cancer cells. Despite these promising results, however, a significant fraction of the mmTGF-β was found to misfold, likely due to mispairing of the cysteines that comprise its cystine knot. Here, we demonstrate that inclusion of a modified form of the TGF-β pro-domain that lacks its dimerization motif, the bowtie knot, dramatically improves both the folding and inhibitory activity upon secretion by mammalian cells, thus overcoming one of the major limitations of genetically delivering mmTGF-β. Furthermore, we show that fusion of mmTGF-β to a CD44 binding domain enhances the inhibitory potential of mmTGF-β on immune cells, and on other cell types which express CD44, by more than 30-fold compared to cells negative for CD44. Together, these modifications provide a framework for further enhancing the efficacy and safety of mmTGF-β for cancer immune therapy, and possibly also tissue fibrosis, when delivered genetically using vaccinia, or other related approaches.
Open AccessPro-domain-dependent folding and co-receptor-mediated targeting to optimize an antagonistic TGF-β monomer for gene-based delivery
Transforming growth factor-beta (TGF-β), a potent promoter of extracellular matrix deposition and suppressor of infiltrating immunity, has arisen as an attractive target for improving outcomes in tissue fibrosis and cancer immune therapy. Despite the promise of TGF-β inhibitors for attenuating the progression of fibrotic disorders or as adjuncts for cancer immunotherapy, current systemically administered inhibitors that target the ligand or receptors have significant on-target liabilities, including cardiotoxicity and development of pre-malignant cutaneous squamous lesions. Recently, an engineered mini monomer of TGF-β (mmTGF-β), which potently and specifically inhibits TGF-β activity, was shown to strongly synergize with checkpoint inhibitors to suppress cancer progression in an aggressive model of melanoma when genetically delivered using an engineered form of vaccinia virus that preferentially infects cancer cells. Despite these promising results, however, a significant fraction of the mmTGF-β was found to misfold, likely due to mispairing of the cysteines that comprise its cystine knot. Here, we demonstrate that inclusion of a modified form of the TGF-β pro-domain that lacks its dimerization motif, the bowtie knot, dramatically improves both the folding and inhibitory activity upon secretion by mammalian cells, thus overcoming one of the major limitations of genetically delivering mmTGF-β. Furthermore, we show that fusion of mmTGF-β to a CD44 binding domain enhances the inhibitory potential of mmTGF-β on immune cells, and on other cell types which express CD44, by more than 30-fold compared to cells negative for CD44. Together, these modifications provide a framework for further enhancing the efficacy and safety of mmTGF-β for cancer immune therapy, and possibly also tissue fibrosis, when delivered genetically using vaccinia, or other related approaches.
- Open Access
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from The C-Terminal Kinase Domain–Binding and Suppression Motif Prevents Constitutive Activation of FGFR2
Key resources. List of antibodies, commercial assays, experimental models, reagents, and software used in this study.
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from The C-Terminal Kinase Domain–Binding and Suppression Motif Prevents Constitutive Activation of FGFR2
Key resources. List of antibodies, commercial assays, experimental models, reagents, and software used in this study.
- Open Access
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Methods from The C-Terminal Kinase Domain–Binding and Suppression Motif Prevents Constitutive Activation of FGFR2
Supplementary Methods related to FLAG and HALO tag constructs.
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Methods from The C-Terminal Kinase Domain–Binding and Suppression Motif Prevents Constitutive Activation of FGFR2
Supplementary Methods related to FLAG and HALO tag constructs.
- Open Access
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S9 from The C-Terminal Kinase Domain–Binding and Suppression Motif Prevents Constitutive Activation of FGFR2
Data supporting the functional analysis of C-terminal F703–S704 combination Fgfr2 variants using in vitro and in vivo methods.
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S9 from The C-Terminal Kinase Domain–Binding and Suppression Motif Prevents Constitutive Activation of FGFR2
Data supporting the functional analysis of C-terminal F703–S704 combination Fgfr2 variants using in vitro and in vivo methods.
- Open Access
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from The C-Terminal Kinase Domain–Binding and Suppression Motif Prevents Constitutive Activation of FGFR2
Proteins identified in Fgfr2-GFP immunoprecipitation samples using MS-based proteomics. The table shows all proteins identified using global proteomics on GFP-immunoprecipitation samples using NMuMG cells expressing GFP, Fgfr2FL-GFP, or Fgfr2DE18- GFP.
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from The C-Terminal Kinase Domain–Binding and Suppression Motif Prevents Constitutive Activation of FGFR2
Proteins identified in Fgfr2-GFP immunoprecipitation samples using MS-based proteomics. The table shows all proteins identified using global proteomics on GFP-immunoprecipitation samples using NMuMG cells expressing GFP, Fgfr2FL-GFP, or Fgfr2DE18- GFP.
- Open Access
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S8 from The C-Terminal Kinase Domain–Binding and Suppression Motif Prevents Constitutive Activation of FGFR2
Histological examination of mammary glands injected with C-terminal F703–S704 Fgfr2 motif variants.
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S8 from The C-Terminal Kinase Domain–Binding and Suppression Motif Prevents Constitutive Activation of FGFR2
Histological examination of mammary glands injected with C-terminal F703–S704 Fgfr2 motif variants.
- Open Access
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S5 from The C-Terminal Kinase Domain–Binding and Suppression Motif Prevents Constitutive Activation of FGFR2
FACS data incl. gating strategy supporting the HALO Fgfr2 internalization analysis and data supporting the biochemical Fgfr2-CT assays
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S5 from The C-Terminal Kinase Domain–Binding and Suppression Motif Prevents Constitutive Activation of FGFR2
FACS data incl. gating strategy supporting the HALO Fgfr2 internalization analysis and data supporting the biochemical Fgfr2-CT assays
- Open Access
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from The C-Terminal Kinase Domain–Binding and Suppression Motif Prevents Constitutive Activation of FGFR2
Data supporting the mapping of the F703–S704 motif in the Fgfr2 C-tail using FACS (gating strategy shown) and RNA-seq.
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from The C-Terminal Kinase Domain–Binding and Suppression Motif Prevents Constitutive Activation of FGFR2
Data supporting the mapping of the F703–S704 motif in the Fgfr2 C-tail using FACS (gating strategy shown) and RNA-seq.
- Open Access
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from The C-Terminal Kinase Domain–Binding and Suppression Motif Prevents Constitutive Activation of FGFR2
Exact P values corresponding to Fig. 4B.
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from The C-Terminal Kinase Domain–Binding and Suppression Motif Prevents Constitutive Activation of FGFR2
Exact P values corresponding to Fig. 4B.
- Open Access
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from The C-Terminal Kinase Domain–Binding and Suppression Motif Prevents Constitutive Activation of FGFR2
Data supporting the in vitro and in vivo Fgfr2-E18 C-tail motif analyses.
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from The C-Terminal Kinase Domain–Binding and Suppression Motif Prevents Constitutive Activation of FGFR2
Data supporting the in vitro and in vivo Fgfr2-E18 C-tail motif analyses.